BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16169463)

  • 1. The Akt-mTOR tango and its relevance to cancer.
    Hay N
    Cancer Cell; 2005 Sep; 8(3):179-83. PubMed ID: 16169463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
    Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
    J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A complex interplay between Akt, TSC2 and the two mTOR complexes.
    Huang J; Manning BD
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
    Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
    J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
    Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
    J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis.
    Radisavljevic ZM; González-Flecha B
    J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
    Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
    Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
    Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
    Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
    Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
    Zhang B; Cao H; Rao GN
    Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.
    Gao N; Zhang Z; Jiang BH; Shi X
    Biochem Biophys Res Commun; 2003 Oct; 310(4):1124-32. PubMed ID: 14559232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
    Sarbassov DD; Guertin DA; Ali SM; Sabatini DM
    Science; 2005 Feb; 307(5712):1098-101. PubMed ID: 15718470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
    Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
    Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation.
    Gerasimovskaya EV; Tucker DA; Stenmark KR
    J Appl Physiol (1985); 2005 Feb; 98(2):722-31. PubMed ID: 15501927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.